Literature DB >> 18973855

Novel application of helical tomotherapy in whole skull palliative radiotherapy.

George Rodrigues1, Slav Yartsev, Terry Coad, Glenn Bauman.   

Abstract

Helical tomotherapy (HT) is a radiation planning/delivery platform that combines inversely planned IMRT with on-board megavoltage imaging. A unique HT radiotherapy whole skull brain sparing technique is described in a patient with metastatic prostate cancer. An inverse HT plan and an accompanying back-up conventional lateral 6-MV parallel opposed pair (POP) plan with corresponding isodose distributions and dose-volume histograms (DVH) were created and assessed prior to initiation of therapy. Plans conforming to the planning treatment volume (PTV) with significant sparing of brain, optic nerve, and eye were created. Dose heterogeneity to the PTV target was slightly higher in the HT plan compared to the back-up POP plan. Conformal sparing of brain, optic nerve, and eye was achieved by the HT plan. Similar lens and brain stem/spinal cord doses were seen with both plans. Prospective clinical evaluation with relevant end points (quality of life, symptom relief) are required to confirm the potential benefits of highly conformal therapies applied to palliative situations such as this case.

Entities:  

Mesh:

Year:  2007        PMID: 18973855     DOI: 10.1016/j.meddos.2007.08.002

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  3 in total

1.  Improve the management of patients with skull bone metastases by means of helical tomotherapy.

Authors:  C Chargari; Y M Kirova; S Zefkili; F Campana
Journal:  Support Care Cancer       Date:  2009-03-17       Impact factor: 3.603

2.  Secondary Cutaneous Involvement in Follicular Diffuse Lymphoma Treated with Helical Tomotherapy.

Authors:  A Rashid Dar; Kevin Jordan; Slav Yartsev
Journal:  Cureus       Date:  2017-07-14

3.  A simpler method for total scalp irradiation: the multijaw-size concave arc technique.

Authors:  Minoru Inoue; Masahiro Konno; Hirofumi Ogawa; Hideyuki Harada; Hirofumi Asakura; Hiroshi Fuji; Shigeyuki Murayama; Tetsuo Nishimura
Journal:  J Appl Clin Med Phys       Date:  2014-07-08       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.